Compare Novo Nordisk A/S (NVO) vs SoundHound AI Inc (SOUN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs SoundHound AI Inc — how do they compare? Novo Nordisk A/S trades at $38.44 (market cap $165.31B), while SoundHound AI Inc trades at $5.4 (market cap $2.45B). The key difference: Novo Nordisk A/S is far larger — about 67.5× SoundHound AI Inc's market cap, and Novo Nordisk A/S pays a 4.71% dividend while SoundHound AI Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and SoundHound AI Inc for 23 Days on average.
| NVO | SOUN | |
|---|---|---|
Market Cap | $165.31B | $2.45B |
Volume | 11,432,838 | 16,881,989 |
Sector | Health | Technology |
52-Week High | $63.98 | $21.40 |
52-Week Low | $35.29 | $5.52 |
Typical Hold Time | 116 Days | 23 Days |
Enterprise Value | $179.56B | $2.25B |
Dividend Yield | 4.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.41, up 0.38% with strong fundamentals including 35.35% net margin and consistent earnings beats. The stock shows bearish technical signals but maintains robust profitability with $102.43B net income. Recent news highlights pipeline developments including Wegovy pill data and FDA reviews, while competition with Eli Lilly intensifies in the obesity drug market.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 59% upside to the $44.67 consensus target. However, technical weakness and competitive pressures from Lilly's new drug candidates pose near-term risks. The company's strong cash flow generation and 59.82% ROE support long-term growth prospects despite regulatory uncertainties.
SoundHound AI (SOUN) trades at $5.49, down 2.49% today, with bearish technical signals but strong analyst support. The company shows robust revenue growth with 2025 revenue of $168.92M and 2026 projected at $203M, though it remains unprofitable with a -67.45% net margin. Recent developments include expansion in restaurant and banking sectors with voice AI technology, while technical indicators show oversold conditions with RSI at 25-29.
The outlook remains speculative with significant execution risk despite 75% analyst buy ratings and a $9.33 consensus target. Key opportunities include voice AI market expansion and enterprise contract wins, while risks center on persistent losses, high valuation multiples, and competitive pressures in the AI sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About SoundHound AI Inc
SoundHound AI, Inc. is a leading innovator in voice artificial intelligence, specializing in conversational intelligence technology. The company develops a platform that allows businesses to add custom voice assistants and natural language processing capabilities to their products and services, ranging from in-car systems and smart speakers to mobile apps and IoT devices. SoundHound's core technology, including its proprietary speech recognition and natural language understanding models, aims to enable fast, accurate, and deeply integrated voice AI experiences across various industries.
Read more on SOUN →
